AD-209

DRUG2 trials

Sponsors

Addpharma Inc.

Conditions

Hypertension, EssentialHypertension,Essential

Phase 2

A Study to Evaluate the Efficacy and Safety of AD-209

CompletedNCT05631990

Addpharma Inc.Hypertension, Essential

Start: 2023-04-05End: 2023-11-27Updated: 2024-04-05

Phase 3

Phase III Study to Evaluate the Efficacy and Safety of AD-209

RecruitingNCT06348576

Addpharma Inc.Hypertension,Essential

Start: 2024-05-20End: 2025-02-28Target: 280Updated: 2024-05-21

Related Papers

Low-Dose TEL/AML/CHTD SPC Versus Standard-Dose TEL in Hypertension: Phase III RCT.

2026-02-20